In our previous study, TAK1 has been shown to phosphorylate RASSF9 at serine 284 to inhibit cell proliferation by targeting the RAS/MEK/ERK axis in ESCC (Shi et al., 2021). This evidence concerns the gene RASSF9 and esophageal squamous cell carcinoma.